Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.

about

Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus-related cirrhosis.

P2860

Q55069588-5E87B029-4CD5-4406-B86B-054905672208

P2860

Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.

Item

http://www.wikidata.org/entity/Q38875903

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Safety of oral direct acting a ...... tis C in real life conditions.

@en

type

Item

label

Safety of oral direct acting a ...... tis C in real life conditions.

@en

prefLabel

Safety of oral direct acting a ...... tis C in real life conditions.

@en

P1476

Safety of oral direct acting a ...... itis C in real life conditions

@en

P2093

Ana Martínez Echeverría

http://www.w3.org/2001/XMLSchema#string

Inmaculada Elizalde

http://www.w3.org/2001/XMLSchema#string

José Manuel Zozaya

http://www.w3.org/2001/XMLSchema#string

Juan Isidro Úriz-Otano

http://www.w3.org/2001/XMLSchema#string

Ramón San Miguel

http://www.w3.org/2001/XMLSchema#string

Silvia Goñi Esarte

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology and genotype distribution of the hepatitis C virus infection

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease.

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.

P304

476-483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00325481.2017.1311197

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P50

J Castilla

Regina Juanbeltz

P577

2017-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28343408

http://www.w3.org/2001/XMLSchema#string

Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.

about

P2860

P2860

Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698